FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum (v13,p594)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MINOTTI, G.
Right arrow Articles by MONTI, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MINOTTI, G.
Right arrow Articles by MONTI, E.
(The FASEB Journal. 1999;13:199-212.)
© 1999 FASEB

Reviews

Role of iron in anthracycline cardiotoxicity: new tunes for an old song?

GIORGIO MINOTTIa , GAETANO CAIROb and ELENA MONTIc

Departments of

a Pharmacology and Pharmacognosy, G. D'Annunzio University School of Pharmacy, Chieti;

b General Pathology, University of Milan School of Medicine, Milan; and

c Structural and Functional Biology, University of Insubria School of Sciences, Varese, Italy

The clinical use of anticancer anthracyclines is limited by the development of a distinctive and life-threatening form of cardiomyopathy upon chronic treatment. Commonly accepted mechanistic hypotheses have assigned a pivotal role to iron, which would act as a catalyst for free radical reactions and oxidative stress. Although perhaps involved in acute aspects of anthracycline cardiotoxicity, the role of free radical-based mechanisms in long-term effects has been challenged on both experimental and clinical grounds, and alternative hypotheses independent of iron and free radicals have flourished. More recently, studies of the role of C-13 hydroxy metabolites of anthracyclines have provided new perspectives on the role of iron in the cardiotoxicity of these drugs, showing that such metabolites can impair intracellular iron handling and homeostasis. The present review applies a multisided approach to the critical evaluation of various hypotheses proposed over the last decade for the role of iron in anthracycline-induced cardiotoxicity. The main goal of the authors is to build a unifying pattern that would both account for hitherto unexplained experimental observations and help design novel and more rational strategies toward a much-needed improvement in the therapeutic index of anthracyclines.—Minotti, G., Cairo, G., Monti, E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song?


Key Words: mechanisms • cardioprotection • metallothionein • DOX




This article has been cited by other articles:


Home page
 Mol. Interv.Home page
Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield, and D. K. St. Clair
Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues
Mol. Interv., June 1, 2007; 7(3): 147 - 156.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Corna, P. Santambrogio, G. Minotti, and G. Cairo
Doxorubicin Paradoxically Protects Cardiomyocytes against Iron-mediated Toxicity: ROLE OF REACTIVE OXYGEN SPECIES AND FERRITIN
J. Biol. Chem., April 2, 2004; 279(14): 13738 - 13745.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
S. FOGLI, P. NIERI, and M. C. BRESCHI
The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage
FASEB J, April 1, 2004; 18(6): 664 - 675.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Cartoni, P. Menna, E. Salvatorelli, D. Braghiroli, R. Giampietro, F. Animati, A. Urbani, P. Del Boccio, and G. Minotti
Oxidative Degradation of Cardiotoxic Anticancer Anthracyclines to Phthalic Acids: NOVEL FUNCTION FOR FERRYLMYOGLOBIN
J. Biol. Chem., February 13, 2004; 279(7): 5088 - 5099.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Bianchi, J. Albanell, W. Eiermann, G. Vitali, D. Borquez, L. Vigano, R. Molina, G. Raab, A. Locatelli, B. Vanhauwere, et al.
Pilot Trial of Trastuzumab Starting with or after the Doxorubicin Component of a Doxorubicin plus Paclitaxel Regimen for Women with HER2-Positive Advanced Breast Cancer
Clin. Cancer Res., December 1, 2003; 9(16): 5944 - 5951.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Ramji, C. Lee, T. Inaba, A. V. Patterson, and D. S. Riddick
Human NADPH-Cytochrome P450 Reductase Overexpression Does Not Enhance the Aerobic Cytotoxicity of Doxorubicin in Human Breast Cancer Cell Lines
Cancer Res., October 15, 2003; 63(20): 6914 - 6919.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Yamanaka, T. Tatsumi, J. Shiraishi, A. Mano, N. Keira, S. Matoba, J. Asayama, S. Fushiki, H. Fliss, and M. Nakagawa
Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes
J. Am. Coll. Cardiol., March 5, 2003; 41(5): 870 - 878.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Y. Kim, A.-G. Ma, K. Kitta, S. N. Fitch, T. Ikeda, Y. Ihara, A. R. Simon, T. Evans, and Y. J. Suzuki
Anthracycline-Induced Suppression of GATA-4 Transcription Factor: Implication in the Regulation of Cardiac Myocyte Apoptosis
Mol. Pharmacol., February 1, 2003; 63(2): 368 - 377.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Kotamraju, C. R. Chitambar, S. V. Kalivendi, J. Joseph, and B. Kalyanaraman
Transferrin Receptor-dependent Iron Uptake Is Responsible for Doxorubicin-mediated Apoptosis in Endothelial Cells. ROLE OF OXIDANT-INDUCED IRON SIGNALING IN APOPTOSIS
J. Biol. Chem., May 3, 2002; 277(19): 17179 - 17187.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Tokarska-Schlattner, T. Wallimann, and U. Schlattner
Multiple Interference of Anthracyclines with Mitochondrial Creatine Kinases: Preferential Damage of the Cardiac Isoenzyme and Its Implications for Drug Cardiotoxicity
Mol. Pharmacol., March 1, 2002; 61(3): 516 - 523.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Minotti, R. Ronchi, E. Salvatorelli, P. Menna, and G. Cairo
Doxorubicin Irreversibly Inactivates Iron Regulatory Proteins 1 and 2 in Cardiomyocytes: Evidence for Distinct Metabolic Pathways and Implications for Iron-mediated Cardiotoxicity of Antitumor Therapy
Cancer Res., December 1, 2001; 61(23): 8422 - 8428.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Minotti, A. Saponiero, S. Licata, P. Menna, A. M. Calafiore, G. Teodori, and L. Gianni
Paclitaxel and Docetaxel Enhance the Metabolism of Doxorubicin to Toxic Species in Human Myocardium
Clin. Cancer Res., June 1, 2001; 7(6): 1511 - 1515.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Kotamraju, E. A. Konorev, J. Joseph, and B. Kalyanaraman
Doxorubicin-induced Apoptosis in Endothelial Cells and Cardiomyocytes Is Ameliorated by Nitrone Spin Traps and Ebselen. ROLE OF REACTIVE OXYGEN AND NITROGEN SPECIES
J. Biol. Chem., October 20, 2000; 275(43): 33585 - 33592.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by The Federation of American Societies for Experimental Biology.